Quest Diagnostics obtained rights to use and sell products and services incorporating Nanogen’s MGB (minor groove binder) Probe technology. According to the end-user license agreement, Quest will pay an up-front fee and royalties on tests sold using this technology. Quest will be able to use this platform in human in vitro diagnostic testing.

Previous articleBroad Institute Taps Complete Genomics to Further Cancer Biomarker Research
Next articleAlnylam and MIT Advance Research on Systemic Delivery of RNAi Therapeutics Using Lipidoid Formulations